The overall objective of this prospective study is to provide a descriptive analysis of the quality of life of pediatric cancer patients enrolled on M.

D. Anderson Cancer Center Protocol 2005-0917, "A Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) with Escalating Doses of Cisplatin for Children with Peritoneal Carcinomatosis or Advanced Peritoneal and Retroperitoneal Disease".

• To examine the quality of life of pediatric patients who undergo CHPP longitudinally. It is hypothesized that physical health and functioning concerns, as reported by parent/child dyads on the Pediatric Quality of Life Cancer Module Version 3.0 (PedsQL) and the PedsQL 4.0 Generic Core Scales, will will remain stable or improve, following the surgical procedures and peritoneal perfusion described in Protocol 2005-0917.
• To assess parent and child perception of the relative benefit of CHPP longitudinally. It is hypothesized that parents and children will perceive CHPP to be beneficial across time, despite the temporary postoperative pain and discomfort that is associated with the procedure. This will be done by means of a non-validated question that is specific to the surgery.
• To determine whether quality of life following CHPP varies by demographic factors (e.g., age, culture), intraoperative cisplatin dose level, or subsequent treatment modalities. Some patients who undergo CHPP might subsequently be treated with other Phase I chemotherapy agents and/or palliative radiation, and comparing quality of life in these subgroups will be of value. Also the quality of life for groups of patients enrolled in Protocol 2005-0917 at each intraoperative cisplatin dose level will be compared.